Introduction
ErbB-2/neu is a member of the receptor tyrosine kinase (RTK) family of growth factor receptors. Although a specific ligand has not been identified, activation of ErbB-2/neu occurs through homo-and heterodimerization with other Erb family members leading to trans-tyrosine phosphorylation and transduction of a mitogenic signal.
1,2 ErbB-2/neu is amplified and overexpressed in 20-30% of human breast cancers and studies in transgenic mice have demonstrated a direct role for this RTK in the process of malignant transformation. 3, 4 Patients with ErbB-2/neu-positive tumors demonstrate a more aggressive clinical course and a poor prognosis. 5, 6 ErbB-2/neu has been evaluated as a potential target for the development of cancer vaccines because pre-existent T cell and Ab responses to ErbB-2/neu have been described in breast cancer patients, although not at a level sufficient to prevent tumor outgrowth. 7, 8 Indeed, elevated anti-ErbB-2/neu T cell responses have been demonstrated in breast and ovarian cancer patients following immunization with peptides derived from the ErbB-2/neu protein. 9, 10 Peptide vaccine-induced T cell responses have also been described in animal models. + and CD8 + T cells were required. In a therapeutic setting, immunization with the DC vaccines could cure mice with pre-established tumors and efficacy was further enhanced by cotransducing DCs with a vector expressing murine IL-12 (AdmIL-12). These studies support DC vaccines as a therapeutic strategy for human breast cancer, while emphasizing the importance of optimizing an immune response by combining tumor antigen presentation with immunostimulatory cytokines. Gene Therapy (2001) 8, 316-323.
However, despite the promising results from these single peptide immunization studies, whether peptide-specific T cell response can be translated to antitumor immunity has yet to be established. In one study, peptide-specific T cells elicited following immunization could lyse target cells pulsed with the peptides from the vaccine inoculum but the T cells were not able to recognize tumor cells that naturally expressed ErbB-2/neu protein. 10 Genetic immunization using a DNA plasmid encoding ErbB-2/neu has been evaluated as a breast cancer vaccine in mouse models. [12] [13] [14] Unlike peptide vaccines, which must be specific for each individual's MHC, expression of plasmid encoded tumor antigens within the host antigenpresenting cells (APC) following vaccination results in the presentation of multiple tumor-associated epitopes in the context of MHC class I and/or class II molecules. Direct intramuscular injection with DNA plasmid expressing ErbB-2/neu induced antigen-specific cellular and humoral immune responses in mice. These animals were partially protected against challenge with ErbB-2/neu-expressing tumor cells 12, 13 and the DNA vaccine could slow tumor development in rat ErbB-2/neutransgenic mice. 14 Recent studies have clearly demonstrated that DNA vaccination requires host dendritic cells (DC) for priming the T cell response, through either direct transfection or antigen transfer from transfected non-hematopoeitic cells. Given that DCs are functionally impaired in cancer patients 15, 16 and in tumor-bearing animals, 17, 18 antigen processing and presentation following genetic immunization may be inefficient in these situations. This impairment can be overcome if the DCs are differentiated ex vivo from precursors present in the peripheral blood. 15 The ex vivo cultured DCs are fully functional and can be used as cellular vectors for vaccines. 19, 20 We, and others, have previously shown that ex vivo transduction of DCs with an adenovirus vector (Ad) expressing a defined tumor antigen can result in a high level of transgene expression in the DCs. 21, 22 Immunization with the genetically modified DCs induces protective immunity and regression of established tumors in a number of murine tumor models. 21, [23] [24] [25] In the current study, we have evaluated a DC/Ad vaccine expressing ErbB-2/neu in a murine model of breast cancer. We demonstrate that immunization with the DC/Ad vaccine is effective in inducing antigen-specific CTL responses leading to protective immunity mediated by CD8 + CTL. More importantly, vaccination with DC/AdNeu TK suppresses the growth of pre-established tumors and this therapeutic effect is further enhanced by cotransduction of the DCs with Ad vector encoding murine IL-12 (AdmIL-12), resulting in a substantial improvement in tumor-free survival.
Results
Expression of rat ErbB-2/neu protein in murine DCs and PTO516 fibroblast cells following AdNeu TK transduction FACS analysis was performed to determine Ad-mediated ErbB-2/neu gene expression in the ErbB-2/neu-negative cell line PTO516 and cultured primary DCs. As shown in Figure 1 , ErbB-2/neu protein was readily detected using Figure 2 . Immunization with AdLacZ-infected DCs did not elicit a measurable ErbB-2/neu-specific CTL response (Figure 2a ), while potent CTL activity against ErbB-2/neu-positive cell line NDL and a syngenic fibroblast cell line PTO516 transduced with AdNeu TK was observed in mice immunized with DC/AdNeu TK (Figure 2b) . Only a background level of cytotoxic lysis to ErbB-2/neu-negative PTO516 target cells was detected in DC/AdNeu TK -immunized mice (Figure 2b ), demonstrating that elicited CTL response by DC/AdNeu TK was ErbB-2/neu specific. The lytic activity against ErbB-2/neu was inhibited by anti-CD3 and anti- Gene Therapy CD8 mAbs indicating that the lytic effectors measured in these experiments were CD8 + T cells ( Figure 2c ). To determine the specific mode of killing, concanamycin A (CMA) and emetin were used to inhibit both perforinand Fas-mediated CTL killing, respectively. 26, 27 CMA treatment completely abrogated CD8 + T cell-mediated cytotoxicity, while emetin only produced a modest loss of cytotoxic activity (data not shown). These observations are consistent with other reports showing that CD8
+ CTL lyse tumor cells predominantly through a cytotoxic granule-dependent pathway. 28 Protection against tumor challenge following immunization with AdNeu TK -transduced DCs To determine if the immune response elicited by the DC/AdNeu TK vaccine was protective against tumor cells expressing ErbB-2/neu, mice were immunized s.c. with either DC/AdNeu TK or DC/AdLacZ and challenged 14 days later with NDL cells. As shown in Figure 3 , nonimmunized animals developed tumors by 20 days after tumor challenge. Complete protection against tumor challenge was observed in 60% of mice immunized with DC/AdNeu TK , lasting for the duration of the experiment (90 days). This protective response was specific for ErbB-2/neu because the NDL tumor grew progressively in mice immunized with DC/AdLacZ and mice vaccinated with DC/AdNeu TK succumbed to challenge with a different breast cancer tumor line that was transformed by the polyoma virus middle T antigen and does not overexpress ErbB-2/neu (data not shown).
Involvement of CD4
+ and CD8 + T cells in protective antitumor immunity The importance of CD4 + in antitumor immunity and CTL priming has been well established through recent studies. Based on our knowledge of antigen processing, we hypo- Figure  5 , unimmunized mice and mice immunized with DC/AdLacZ had a large tumor burden 20 days following tumor implantation, and those mice had to be killed within 30-40 days because their tumor volumes were above 800 mm 3 . In contrast, treatment with DC/AdNeu TK resulted in substantially reduced tumor burden until day 40 (P Ͻ 0.01, DCAdNeu TK compared with naive and DCAdLacZ) and 30% of treated mice were tumor free at the termination of the experimental period.
Since IL-12 has been shown to be critical in DC function both as a paracrine factor to enhance CTL and Th1 cell activation and as an autocrine factor for DC maturation, 32, 33 we evaluated whether cotransduction of DCs with AdmIL-12 and AdNeu TK could further enhance antitumor immunity in our therapeutic model. To determine whether cotransduction would suppress gene expression from one of the vectors, DCs were transduced with either AdLacZ, AdmIL-12 or both and gene expression was evaluated 48 hours later. DCs transduced with AdmIL-12 alone at a MOI of 100 or cotransduced with AdmIL-12 and AdLacZ, at a MOI of 100 each, produced 160-170 ng/10 6 cells, while IL-12 levels from DCs transduced with AdLacZ alone were less than 0.07 ng/10 6 cells ( Table 1 ). We also examined the expression of LacZ in DCs transduced with either AdLacZ alone or AdLacZ in combination with AdmIL-12 by X-gal staining. In both groups, more than 90% of DCs expressed LacZ 48 h after infection at a MOI of 100 (Table 1 ). These data demonstrate the flexibility of the DC/Ad vaccine in that multiple vectors can be used to transfer both tumor antigen and adjuvant cytokines. In the therapeutic model, no tumors were apparent in mice treated with DCs co-transduced with AdNeu TK and AdmIL-12 at day 40 after tumor cell inoculation ( Figure  5 ) and more than 66% of treated mice remained tumor free for the duration of the experiment (Table 2) , demonstrating an adjuvant effect of IL-12 in DC cancer vaccination (P Ͻ 0.05, DCAdNeu TK /AdmIL-12 versus DCAdNeu TK ). These results were a combined effect of both ErbB-2/neu and IL-12 expression in the DC inoculum because DCs transduced with AdmIL-12 alone had no inhibitory effect on tumor growth (Table 2) . Thus, in this model, the ability to combine multiple Ad vectors in a single DC inoculum can confer increased therapeutic properties not offered by the basic DC/Ad vaccine expressing tumor antigen alone.
Discussion
In this study we have evaluated a novel vaccination strategy for breast cancer using genetically modified DCs. The results show that immunization of FVB/n mice with DCs transduced with an Ad vector encoding modified ErbB-2/neu (DC/AdNeu TK ) can elicit antigen-specific CTL responses and protect mice against a challenge with tumor overexpressing ErbB-2/neu. More importantly, the DC/AdNeu TK vaccine could successfully cure mice of Clinical studies involving immunization with peptides derived from the ErbB-2/neu protein could activate antigen-specific CD4 + and CD8 + T cells in breast cancer patients, yet generation of a cellular response against ErbB-2/neu peptide has not correlated with tumor rejection. 9, 10 Refinement of the peptide vaccines is hampered by the lack of defined tumor-rejection peptides from ErbB-2/neu, so alternative strategies are needed. DCs are the most effective APC and genetic modification of DCs with tumor antigen-encoding genes should result in multiple epitope presentation in the context of MHC class I and/or class II molecules; therefore this approach bypasses the need for peptide identification. We have chosen to use Ad vectors for DC gene transfer because these viruses can transduce DCs with high efficiency and easily allow the introduction of multiple vectors into the same DC population. In addition, we have previously demonstrated that the DC/Ad vaccine could overcome the Ad-associated hepatic toxicity and was efficacious in mice with pre-existing anti-Ad immunity, suggesting the potential of the DC/Ad system as a clinical vaccination regimen. 21, 34 To limit the possibility of deleterious consequences, the transforming activity of the ErbB-2/neu molecule used in our vaccine has been inactivated by a single amino acid substitution (lysine to alanine), unlike other reports where the entire intracellular domain was removed.
35 By virtually retaining the entire ErbB-2/neu molecule, we have maximized the potential repertoire of ErbB-2/neu peptides in the DC/Ad vaccine. Chen et al 12 showed that plasmid DNA encoding a truncated rat ErbB-2/neu that lacked the intracellular domain could induce protective immunity against ErbB-2/neu-expressing mammary tumors as effectively as plasmid encoding the full-length ErbB-2/neu oncogene, arguing that the intracellular domain offered no advantage. Evidence from clinical trials, however, demonstrated that CD4 + T cells recognizing peptides from both extracellular and intracellular domains of human ErbB-2/neu protein can be induced by peptide vaccination and it has been suggested that the intracellular domain may represent a better immune target given its limited exposure to the external environment. 9 Conceptually, vaccination with the full-length DNA through ex vivo targeting of the DCs should have the advantage of presenting the complete repertoire of ErbB-2/neu epitopes in association with MHC class I and class II molecules, maximizing the number of peptide epitopes available for T cell recognition. T cell reactivity against a broad range of target peptides should also reduce the incidence of immune escape by antigen-loss variants.
The DC/Ad vaccine described in this article was highly effective in inducing CTL activity and antitumor immune response against ErbB-2/neu-expressing tumors in a CD4-dependent manner. We observed the complete loss of tumor protection when CD4 + or CD8 + T cells were depleted during the immune priming phase (days 1 to 14 following vaccination) before tumor challenge, suggesting that both CD4 + and CD8 + T cells are required for the induction of antitumor immune response. When mice were treated with anti-CD4 or anti-CD8 mAb immediately before tumor challenge, only the depletion of CD8 cells resulted in abolition of protective immunity. These in vivo results strongly support recent arguments emphasizing a critical role for CD4 + T cells in the induction of CD8 + CTL. 36 Additionally, our in vivo studies concur with our in vitro CTL analysis where we observed cytotoxic activity in spleens from DC/AdNeu TK -immunized mice that was mediated by CD8 + T cells through the classic perforin-dependent pathway. Our results provide evidence for the first time that genetic immunization with modified ErbB-2/neu oncogene can activate both CD4 + and CD8
+ T cells which directly correlate with protective antitumor immunity.
The efficacy of the DC/AdNeu TK vaccine was also evaluated in a therapeutic setting using mice with preestablished NDL tumors. A single treatment with DC/AdNeu TK significantly suppressed tumor growth and resulted in long-term survival in 30% of the mice. This therapeutic effect was further improved by cotransduction of DCs with AdNeu TK and AdmIL-12, leading to a delay in tumor growth in 100% of treated mice and 66% of these animals remained tumor free for more than 3 months. Our results agree with the observations that transfection with the IL-12 gene dramatically enhances the efficacy of DC-based antitumor and anti-bacterial vaccines in murine models. 37, 38 High levels of IL-12 production can be achieved through transduction of the DCs with Ad vector encoding IL-12 gene and it is expected that paracrine secretion of IL-12 at the site of antigen presentation would induce a more potent immune response. Moreover, enhanced antitumor immunity by cotransduced DCs may be attributed to IL-12-induced DC maturation since up-regulation of B7-2 and CD40 was consistently observed in our cultured DCs following AdmIL-12 transduction (data not shown). This incorporated DC vaccination approach may be particularly useful in the scenario where a given tumor antigen is subject to self tolerance. As such, we expect that it will be more difficult to induce protective antitumor immunity in rat ErbB-2-transgenic mice than our current transplant tumor model, even using the DC/Ad vaccine to present ErbB-2 antigens, because tolerogenic response to rat ErbB-2 is relatively stringent in transgenic background. Whether cotransduction of DCs with AdNeu TK and AdmIL-12 can break self tolerance in rat ErbB-2-transgenic mice to achieve prevention of spontaneous tumor development is under testing in our laboratory.
In conclusion, these studies support the use of the DCbased vaccine as a therapeutic strategy to target both CD4 + and CD8 + T cells and emphasize the flexibility of this system for optimizing an immune response by combining tumor antigen presentation with immunostimulatory cytokines. The high efficiency of Ad-mediated gene transfer and ease of Ad construction/production make this a practical and promising approach for the development of novel immunotherapeutic strategies for human tumors overexpressing ErbB-2/neu.
Materials and methods
Mice Female FVB/n (H-2 q ) mice, 6 to 8 weeks old, were purchased from the Charles River Laboratories (Wilmington, DE, USA) and housed under standard conditions speci-fied by the Canadian Council on Animal Care at McMaster University.
Cell lines PTO516 is a kidney fibroblast cell line derived from a normal FVB/n mouse. The NDL cell line was generated from a tumor that developed on a transgenic mouse harboring a mutated rat ErbB-2/neu transgene under the control of the MMTV promoter. 39 These cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat inactivated fetal bovine serum (FBS). All cell culture reagents were purchased from GIBCO (Grand Island, NY, USA).
Adenoviral vectors
The full-length cDNA for rat ErbB-2/neu was used to construct the Ad vector. For safety, a point mutation was introduced in codon 758 converting a lysine to an alanine residue at the putative ATP binding site. Previous studies demonstrated that this single amino acid replacement inactivated the kinase activity of ErbB-2/neu. 35 The kinase-inactive open reading frame for rat ErbB-2/neu (Neu TK ) was isolated from the plasmid pJ4 Neu N and subcloned into the Ad5 shuttle vector, pMH5. The shuttle plasmid was then cotransfected with the rescue vector pBHG10 into 293 cells to generate the AdNeu TK vector. The construction of AdmIL-12 and AdLacZ has been previously described. 40, 41 Flow cytometric analysis To measure ErbB-2/neu expression, PTO516 cells and DCs were infected with AdNeu TK at a multiplicity of infection (MOI) of 100 (AdLacZ was used as a control) for 24 h. Cells were washed in PBS and incubated with anti-ErbB-2/neu mAb Ab-4 (Oncogene Research Products, Boston, MA, USA) at 4°C for 40 min. These cells were washed twice, then incubated at 4°C for another 40 min with fluorescein-conjugated goat anti-mouse IgG Ab. The fluorescence intensity was measured using a FACScan cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
Preparation of bone marrow DCs and infection with Ad vectors
Bone marrow DCs were generated as previously described. 21 Briefly, erythrocyte-depleted bone marrow cells were collected and cultured in complete medium (CM) (RPMI 1640 containing 10% FBS, 50 m 2-ME, 2 mm glutamine, 0.1 mm nonessential amino acids, and 100 g/ml penicillin and 100 U/ml streptomycin), supplemented with 10 ng/ml murine GM-CSF and 10 ng/ml murine interleukin-4 (Schering-Plough Research Institute, NJ, USA). On day 2 of culture, non-adherent cells were gently removed, and fresh medium was added and maintained for an additional 3 days. At 5 days of culture, nonadherent cells and loosely adherent proliferating aggregates were collected for analysis and immunizations. A panel of selected phenotypic markers including MHC class II, B7-2, CD40, and CD11c, was used to characterize cultured DCs by flow cytometry (data not shown).
Transduction of DCs with Ad vectors was performed on day 4 of culture. DCs were infected with AdNeu TK (DC/AdNeu TK ), AdmIL-12 (DC/AdmIL-12) or AdLacZ (DC/AdLacZ) at a MOI of 100 and cultured for 24 h. In some experiments, DCs were infected with AdNeu TK in + T cells (hybridoma 53.6.72; ATCC) was performed by intraperitoneal injection of 100 l of ascites diluted in a volume of 500 l of phosphate-buffered saline (PBS). Two antibody depletion protocols were assessed. The first protocol (priming phase depletion) was initiated 2 days before immunization and then every 3rd day until day 14 after immunization, at which point animals were challenged with 7 × 10 6 NDL cells by s.c. injection in the left hind flank. In the second protocol, antibody treatment was initiated 2 days before tumor challenge then every 3rd day until most control animals (immunized with PBS and challenged with NDL cells) developed palpable tumors. The efficiency of specific antibody depletion of CD4 + and CD8 + T cells in spleens was more than 90% by flow cytometry (data not shown).
Suppression of pre-established subcutaneous tumors by DC/Ad vaccination FVB/n mice were inoculated s.c. with 7 × 10 6 NDL cells 3 days before the initiation of immune therapy. Animals were either left untreated, or treated with s.c injection of DC/AdNeu TK or DC/AdLacZ. To determine whether the cotransduction of DCs with AdNeu TK and AdmIL-12 can enhance antitumor immunity, one group of tumor-bearing mice were treated with two vector-transduced DCs and DCs transduced with AdmIL-12 alone was also included as a control. The tumor size was measured weekly and mice were killed when tumors became ulcerated or when tumor volume reached 800-1000 mm 3 .
Cytotoxicity assays
Splenocytes were isolated from FVB/n mice 14 days after immunization with the DC/Ad vaccine and restimulated in vitro with irradiated NDL cells (5000 rad) at a responder to stimulator ratio of 50:1. Five days later, effector cells were harvested and mixed with 51
Cr-labeled target cells at various E:T ratios. NDL and PTO516 transduced with AdNeu TK were used as target cells for ErbB-2/neu-specific CTL assays and PTO516 cells alone were used as a non-ErbB-2/neu expressing control. The mixtures were incubated in 96-well plates at 37°C for 4 h. In inhibition experiments, a 10 l aliquot of purified anti-CD3 mAb (PharMingen, Ontario, Canada) or ascites containing mAb specific for CD4 + (GK1.5; ATCC) or CD8 + T (53.6.72; ATCC) cells was added to the wells. Effector cells were also preincubated with 100 nm of concanamycin A (CMA; Sigma) or 5 nm of emetin (Sigma, St Louis, MO, USA) for 2 h selectively to prevent perforin (CMA)-
